Introduction
LINC00460 expression in malignancies
Cancer type | Expression in tissue | Sample size | Expression in cancer cells | Cancer cell lines | Relative normal cell lines | Functional role | Refs. |
---|---|---|---|---|---|---|---|
Acute myeloid leukemia | Up | 80 | Up | THP1, KG1, ME1, HL60 | HS5 | Proliferation, apoptosis, cell cycle | [36] |
Bladder cancer | Up | 43 | Up | T-24, 5637,SW780, RT-112 | SV-HUC-1 | Proliferation, migration, invasion | [13] |
– | – | Up | 5637, T24 | SV-HUC-1 | Proliferation, migration | [14] | |
Breast cancer | Up | 42 | Up | MCF-7, BT-474, MDA-MB-231, BT-549 | MCF-10 A | Proliferation, migration, invasion | [15] |
Cervical cancer | Up | 20 | Up | HeLa, CaSki | – | Proliferation, invasion, cell cycle | [16] |
Up | 30 | – | SiHa, C-33 A, HeLa, CaSki | – | Proliferation, apoptosis, cell cycle | [17] | |
Colon cancer | – | – | Up | HT-29, HCT-116, SW480, LOVO | NCM-460 | Proliferation, invasion, EMT | [19] |
Up | 36 | Up | H460, A549, SK-MES-1, and H1299) | NHBE | Invasion, chemoresistance | [18] | |
Colorectal cancer | Up | 60 | Up | HCT116, SW480, HT-29, Lovo | HcoEpiC | Proliferation, apoptosis | [10] |
Up | 92 | Up | SW620, HCT116, CX-1, HT29 | NCM460 | proliferation, cell cycle | [24] | |
Up | 74 | Up | HT29, HCT116, SW480, and LOVO | NCM460 | Proliferation, migration, invasion, apoptosis | [21] | |
Up | 62 | Up | HCT-15, HCT-116, SW480, SW620, RKO, LoVo, HT-29 | CCD841CoN | Proliferation, migration, invasion, EMT | [60] | |
Up | 74 | Up | HT29, HCT116, SW480, LOVO | NCM460 | Pigration, invasion | [22] | |
Up | 498 | Up | SW480, SW620, HCT116, DLD1, LOVO, HT29 | FHC | Proliferation, migration, invasion | [20] | |
Up | 40 | Up | HCT116, HT–29 | FHC | Migration, invasion | [23] | |
Up | 21 | – | – | – | Chemoresistance | [64] | |
Epithelial ovarian cancer | Up | 98 | Up | SKOV3, A2780, OVCAR, HO–8910 | HOSEpiC | – | [28] |
Esophageal cancer | – | – | Up | EC1, EC9706, KYSE70, TE1, TE13 | Het-1 A | Migration, invasion, EMT | [61] |
Up | 65 | Up | EC109, KYSE150, KYSE450 | Het-1 A | Proliferation, apoptosis | [25] | |
Gastric cancer | Up | 60 | Up | MGC803, BGC823 and SGC7901) | GSE1 | Proliferation, migration, invasion, cell cycle | [53] |
Up | 80 | Up | (BGC823, AGS, SGC7901, and MGC803 | GES1 | Proliferation, apoptosis, cell cycle | [26] | |
Up | 90 | Up | BGC-823, SGC-7901, MKN-28, MKN-45 | GES-1 | Proliferation, invasion, cell cycle | [27] | |
Glioma | Up | 42 | Up | U87, U251, LN229, A172 | NHA | Proliferation, migration, invasion, apoptosis | [37] |
Head and neck squamous cell carcinoma | Up | 15 | Up | CAL-27, WSU-HN4, WSUHN6 | HOEC | Proliferation, migration,EMT, apoptosis | [38] |
Up | 60 | Up | HSC3, Fadu, SAS | HACA | Proliferation, migration, invasion, EMT | [39] | |
Up | 123 | Up | WSU–HN4, WSUHN6, WSU-HN30, SCC-4, SCC-9, SCC-25 and CAL-27 | Normal oral epithelial cells | Proliferation, migration, invasion, EMT | [41] | |
Up | 54 | – | PCI-13, FaDu, SCC-15, UM-SCC-10 A | – | Apoptosis, autophagy, cell cycle | [42] | |
Hepatocellular carcinoma | Up | 60 | Up | SNU423, Hep3B, HuH7, SK-Hep-1 | HS-5 | Proliferation, migration, invasion, apoptosis | [43] |
Up | 60 | Up | HepG2, Hep3B, SNU-449, THLE-3, HCCLM3, | Huh-7, LO2 | Proliferation, migration, invasion, apoptosis | [44] | |
Up | 50 | Up | HepG2, Huh7, SMMC7721, BEL-7402,HCCLM3, SK-HEP-1 | LO2 | Proliferation, migration, invasion, cell cycle | [45] | |
Laryngeal squamous cell carcinoma | Up | 68 | – | – | – | – | [46] |
Lung cancer | Up | 50 | Up | H157, 95D, SPC-A-1, A549, SK-LU-1, Calu-3, HCC-78, H1299, H1975 | 16HBE | Proliferation | [11] |
Up | 52 | Up | A549, H226, H1915, SPCA–1, PC–9 | 16HBE | Proliferation, migration, invasion, EMT | [29] | |
Up | 36 | Up | H460, A549, SK-MES-1, and H1299 | NHBE | Proliferation, invasion, chemoresistance | [30] | |
Up | 8 | Up | A549, H1299, H1975, H460, PC9, SPC-A1 | Beas-2B | Migration, invasion, EMT | [31] | |
Meningioma | Up | 33 | Up | (IOMM-Lee, CH157-MN) | Ben–Men-1 | Proliferation, invasion, apoptosis | [47] |
Nasopharyngeal carcinoma | Up | 50 | Up | SUNE-1, CNE-1, HNE-1, CNE-2, C666-1, HONE-1 | NP69 | Proliferation | [48] |
Osteosarcoma | Up | 31 | Up | Saos-2, HOS, U2OS, MG63 | hFOB 1.19 | Proliferation, migration, invasion | [49] |
Pancreatic cancer | Up | 59 | – | – | – | Proliferation | [32] |
Papillary thyroid cancer | Up | 58 | Up | 5CTPC1, BCPAP, FTC-133, 8505 C | Nthyori 3-1 | Proliferation, migration, invasion, EMT | [33] |
Up | 48 | Up | TPC-1, BCPAP, IHH-4 | Nthyori 3-1 | Proliferation, migration, invasion | [34] | |
– | – | Up | K1, TPC-1 | Nthyori 3-1 | Proliferation, invasion, apoptosis | [35] |
Regulation of LINC00460 in cancer
LINC00460 functions in malignancies
LINC00460 in cell viability and proliferation
Cancer type | Cancer cell lines | Animal | Role in tumor growth | Refs. |
---|---|---|---|---|
Bladder Cancer | T-24 | BALB/c nude mice | Promote | [59] |
Breast cancer | MCF-7 | Nude mice | Promote | [15] |
Cervical cancer | HeLa, CaSki | Nude mice | Promote | [16] |
SiHa | Nude mice | Promote | [17] | |
Colon cancer | HCT-116, LOVO | BALB/c nude mice | Promote | [19] |
Colorectal cancer | HCT116 | Nude mice | Promote | [20] |
HCT116, SW480 | BALB/c nude mice | Promote | [10] | |
HT29 | BALB/c nude mice | Promote | [21] | |
RKO | BALB/c nude mice | Promote | [60] | |
Gastric cancer | BGC823 | Athymic mice nude mice. | Promote | [26] |
MKN-45 | Nude mice | Promote | [27] | |
Head and neck squamous cell carcinoma | CAL-27 | BALB/c nude mice | Promote | [41] |
Fadu | BALB/c nude mice | Promote | [39] | |
Hepatocellular carcinoma | Hep3B | BALB/c nude mice | Promote | [44] |
HepG2 | BALB/c nude mice | Promote | [45] | |
HuH7 | BALB/c nude mice | Promote | [43] | |
Lung cancer | A549, SPC-A-1 | BALB/c nude mice | Promote | [11] |
A549 | Nude mice | Promote | [30] | |
Nasopharyngeal carcinoma | 5-8 F | BALB/c nude mice | Promote | [62] |
CNE-1, SUNE-1 | BALB/c nude mice | Promote | [48] | |
Papillary thyroid cancer | TPC1 | BALB/c nude mice | Promote | [33] |
LINC00460 in cell death
LINC00460 in cancer metastasis
LINC00460 in chemotherapeutic or radiation resistance
Mechanisms underlying LINC00460’s effects in malignancies
LINC00460 serves as a ceRNA
LINC00460 target miRNA | Validated method | miRNA target gene | Cancer type | Refs. |
---|---|---|---|---|
miR-1224-5p | Luciferase reporter assay | – | Esophageal cancer | [61] |
miR-1224-5p | Luciferase reporter assay, RIP | FADS1 | osteosarcoma | [49] |
miR-149-5p | Luciferase reporter assay, RIP | CUL4A | colorectal cancer | [10] |
miR-149-5p | Luciferase reporter assay, RNA pull–down | IL6 | nasopharyngeal carcinoma | [48] |
miR-149-5p | Luciferase reporter assay | BGN | colorectal cancer | [23] |
miR1495p | Luciferase reporter assay, RIP | IL6 | Lung adenocarcinoma | [51] |
miR-149-5p, miR-150-5p | Luciferase reporter assay, RNA pull–down | p53 | Colorectal Cancer | [64] |
miR-206 | Luciferase reporter assay, RNA pull–down | STC2 | Head and neck squamous cell carcinoma | [42] |
miR-302c-5p | Luciferase reporter assay, RNA pull–down | FOXA1 | Lung adenocarcinoma | [11] |
miR30a3p | Luciferase reporter assay, RNA pull–down | – | Nasopharyngeal carcinoma | [62] |
miR-320a | Luciferase reporter assay | – | Glioma | [37] |
miR320b | Luciferase reporter assay | PBX3 | Acute myeloid leukemia | [36] |
miR-338-3p | Luciferase reporter assay | – | Epithelial ovarian cancer | [28] |
miR-342-3p | Luciferase reporter assay, RIP | KDM2A | Gastric cancer | [53] |
miR-342-3p | Luciferase reporter assay, RNA pull–down | AGR2 | Hepatocellular carcinoma | [45] |
miR-342-3p | Luciferase reporter assay | AGR2 | Hepatocellular carcinoma | [43] |
miR3613p | Luciferase reporter assay | Gli1 | Cervical cancer | [16] |
miR-433-3p | Luciferase reporter assay, RNA pull–down | ANXA2 | Colon cancer | [19] |
miR-4443 | Luciferase reporter assay | – | Head and neck squamous cell carcinoma | [38] |
miR-485-5p | Luciferase reporter assay | Raf1 | Papillary thyroid cancer | [33] |
miR-485-5p | Dual luciferase reporter assay, RNA pull–down assay, RIP | PAK1 | Hepatocellular carcinoma | [44] |
miR-489-5p | Luciferase reporter assay, RNA pull–down | FGF7, AKT | Breast cancer | [15] |
miR-5035p | Luciferase reporter assay | AKT2, HMGA2, SHOX2 | Cervical cancer | [17] |
miR-539 | Luciferase reporter assay | MMP–9 | Meningioma | [47] |
miR-539 | Luciferase reporter assay | MMP–9 | Papillary thyroid carcinoma | [35] |
miR-612 | Luciferase reporter assay, RIP | AKT2 | Head and neck squamous cell carcinoma | [39] |
miR-612 | Luciferase reporter assay | FOXK1 | Bladder Cancer | [59] |
miR-613 | Luciferase reporter assay, RIP | SphK1 | Colorectal cancer | [21] |
miR-939-5p | Luciferase reporter assay, RNA pull–down | LIMK2 | Colorectal cancer | [22] |
LINC00460 interacts with RNA binding proteins
LINC00460 as a cancer biomarker
LINC00460 as a molecular marker for cancer diagnosis
LINC00460 serves as a biomarker for cancer prognosis
Cancer type | Prognostic indicator | Associated clinical features | Refs. |
---|---|---|---|
Acute myeloid leukemia | OS, PFS | FAB classification, cytogenetics | [36] |
Bladder cancer | OS | Tumor stage, lymph nodes metastasis | |
Breast cancer | OS | Tumor size, WHO stage | [15] |
Cervical cancer | OS | – | |
Colon cancer | OS | – | [18] |
Colorectal cancer | OS, DFS | Tumor stage, metastasis classification, lymph node metastasis, TNM stage | |
Esophageal squamous cell carcinoma | OS | TNM stage, lymph node metastasis, differentiation degree | [25] |
Gastric cancer | OS, DFS | TNM stage, lymph node metastasis | |
Head and neck squamous cell carcinoma | OS | Tumor stage, tumor differentiation, lymph node metastasis, TNM stage, | |
Hepatocellular carcinoma | OS, PFS | Tumor differentiation degree, TNM stages, lymph node metastasis | |
Lung cancer | OS, PFS | – | |
Nasopharyngeal carcinoma | OS | – | |
Osteosarcoma | OS, DFS | Tumor size, distant metastasis | |
Pancreatic cancer | OS | Tumor size | [32] |
Papillary thyroid carcinoma | OS | TNM stage, lymph node metastasis |